Proton Pump Inhibitors May Trigger Osteoporosis Development and Progression
Abstract
Proton pump inhibitors (PPIs) are commonly prescribed in conjunction with other drugs as preventative means. Their primary function is acid suppression, as such, they subsequently hold back intestinal calcium absorption. By this mechanism, chronic use of PPIs is suggested to induce osteoporosis -- a condition that gradually increases bone fragility and is associated with high suffering and morbidity rates. Additionally, PPI administration amongst elderly patients for more than one year has been shown to have an increased risk for hip fractures. This current review consists of literature searches from PubMed and The National Library of Medicine (USA). It analyzes factors such as age, race, gender, menopausal status, lifestyle, medical conditions, and polypharmacy which may induce osteoporosis, and explores the mechanism of how PPIs may trigger osteoporosis development and/or progression. Clinicians should be cautious of severe osteoporosis as a potential consequence to PPI-use, and be aware that it can be mitigated by appropriate selection of pharmacological therapies and modalities.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.